Key result
Promoting endogenous cardiac regeneration by targeting DYRK1A to induce cardiomyocyte proliferation is a promising approach for treating myocardial injury and heart failure.
Why the study?
The adult mammalian heart has very limited regenerative capacity, leaving cardiomyocyte loss uncorrected after myocardial injury and lacking clinical therapies to stimulate cardiac regeneration.
Targeting DYRK1A is highlighted as a promising approach to promote endogenous cardiac regeneration by inducing proliferation of pre-existing cardiomyocytes.
Should not change practice; hypothesis-generating for DYRK1A inhibition in cardiac regeneration.
Due to the fact that the mammalian adult heart has a very limited regenerative capacity of the myocardium, cardiomyocyte loss cannot be corrected following myocardial injury. Sustained cardiomyocyte loss can further cause cardiac remodeling and heart failure. Although clinical therapies to stimulate cardiac regeneration was currently unavailable, increasing evidence has emerged that promoting the endogenous cardiac regeneration by inducing the proliferation of pre-existing cardiomyocytes is an effective and promising approach to treat myocardial injury and heart failure.
No takes yet. Share an insight, caveat, or question.
Bei et al. (2022) conducted a review in Myocardial injury and heart failure. DYRK1A targeting was evaluated. Promoting endogenous cardiac regeneration by targeting DYRK1A to induce cardiomyocyte proliferation is a promising approach for treating myocardial injury and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: